JRC News

  1. 25 Mar 2015

    A new treatment for bladder carcinoma is being developed by the JRC and Munich’s Technical University hospital Klinikum rechts der Isar. Recently, the first in-human tests have been conducted showing positive results.

  2. 13 Jan 2015

    The Institute for Transuranium Elements (JRC-ITU) of the European Commission, the Medical University Warsaw and Eckert & Ziegler Eurotope invite you to the 9th Symposium on Targeted Alpha Therapy.

  3. 29 Oct 2014

    A study evaluating the immunogenicity of tumour cells after they have been irradiated with the alpha particle emitter bismuth-213 (213Bi) showed resistance to further tumour challenge.

  4. 12 Jun 2012

    A picture is worth a thousand words. This is the reason why the image shown has been awarded the title of "image of the year" by the Society of Nuclear Medicine (SNM). It comes from a study led by the Joint Research Centre´s (JRC) Institute for Transuranium Elements (ITU) and conducted in collaboration with University Hospital Heidelberg

  5. 1 Dec 2011

    Invasive fungal infections (IFI) are a major threat to individuals with cancer, transplants, HIV, and other conditions that weaken their immune system. New research has shown that radioimmunotherapy (RIT) could be a promising avenue for development of new types of treatment of fungal diseases. The research is published in a paper co-authored by JRC scientists in the framework of collaboration with the Albert Einstein College of Medicine (AECM) in New York.

  6. 20 Jul 2011

    Experts from medicine, biology, chemistry and physics gathered in Berlin on 18 and 19 July for the 7th Symposium on Targeted Alpha Therapy, organised by the JRC's Institute for Transuranium Elements (ITU) and engineering company Eckert & Ziegler Eurotope GmbH.

  7. 9 Jun 2011

    A joint JRC – University of Heidelberg study on a highly effective therapy for neuro-endocrine cancer received the Young Investigator Award of the Society of Nuclear Medicine (SNM) in San Antonio, USA, at their annual meeting on 4-8 June. The paper “Regional 213Bi-DOTATOC peptide receptor alpha-therapy in patients with neuro-endocrine liver metastases refractory to beta-radiation” is the result of research conducted by a group of scientists of JRC’s Institute for Transuranium Elements (ITU) and fellow colleagues from the University of Heidelberg.

  8. 22 Oct 2009

    At this year's Annual Congress of the European Association of Nuclear Medicine (EANM 2009), the JRC's work in the field of alpha immunotherapy received special recognition. The presentation by Frank Bruchertseifer of the JRC Institute for Transuranium Elements (ITU) was nominated for the EANM 2009 Marie Curie Award and received the Eckert and Ziegler Award (Top 5 papers presented by young investigators below 38 years of age). The paper describes methods for the production of the alpha emitters Th-226 and Bi-213 and compares their therapeutic efficacy in vitro and in vivo.

  9. 14 Feb 2009

    Today at the annual meeting of the American Association for the Advancement of Science (AAAS) in Chicago, Ekaterina Dadachova of the Albert Einstein College of Medicine in New York gave a topical lecture on "Novel approaches to the therapy of infectious diseases", detailing the results of a joint project with scientists at the JRC Institute for Transuranium Elements (ITU) on the use of alpha-immunotherapy as a new option for the treatment of HIV infections.

  10. 13 Nov 2008

    A joint study involving JRC scientists Frank Bruchertseifer and Alfred Morgenstern from the Institute for Transuranium Elements (ITU) and collaborators from Klinikum Rechts der Isar (KRDI) in Munich has won the 2008 Marie Curie Award of the European Association of Nuclear Medicine.